Adrenoleukodystrophy: Biochemical procedures in diagnosis, prevention and treatment
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
The childhood form of adrenoleukodystrophy is an X‐linked recessive disorder which is characterized biochemically by elevated concentrations of saturated very long chain fatty acids in tissues and plasma and impaired very long chain fatty acid oxidation in fibroblasts and leukocytes from adrenoleukodystrophy patients. The most consistently observed increase is that in hexacosanoic acid (C26:0); thus, measurement of plasma C26:0 concentration by gas‐liquid chromatography provides a rapid, sensitive method of diagnosis. Prenatal diagnosis of adrenoleukodystrophy can be made by measurement of C26:0 concentrations in amniocytes and chorionic villus cells. Heterozygote (carrier) detection has also been accomplished by biochemical measurement of C26:0 in plasma and skin fibroblasts. In a study of over 200 obligate heterozygotes, >90% showed abnormal concentrations of C26:0. Hybridization studies using the cloned DNA fragment St14 detects polymorphisms in the distal end of the long arm of the X chromosome (Xq27–28) and six informative kindreds have shown co‐segregation of adrenoleukodystrophy and the St14 marker through 65 meioses. Thus, such studies can supplement very long chain fatty acid concentrations in heterozygote detection. Therapeutic interventions for adrenoleukodystrophy, such as dietary restriction of very long chain fatty acids, administration of clofibrate or carnitine, immunosuppression and adrenal hormone replacement, have not been successful. Recently, a modification of the very long chain fatty acid‐restricted diet has been employed in which this diet is supplemented with synthetic glycerol trioleate. The rationale for this diet is that decreased very long chain fatty acid synthesis by fibroblasts from patients with adrenoleukodystrophy was observed when oleic acid was added to the culture medium. In a study of 14 patients on this diet from 2 to 11 months, there was a mean reduction in plasma C26:0 levels of 46%, with one patient achieving a normal plasma level. The effect of lowering plasma very long chain fatty acid concentrations on the neurologic status of patients with adrenoleukodystrophy and on the development of symptoms in asymptomatic individuals with elevated very long chain fatty acid concentrations remains to be established.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ALD is thus characterized by high ratios of C 26 to C 22 very long chain fatty acids in plasma and tissues, permitting accurate diagnosis (35).”
From The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders (2011) · cites this paper as [35]
Citations
Cites
Qualitative alteration in substrate specificity of mitochondrial monoamine oxidase in brain
Moskvitina, T. A., Kamyshanskaya, N. S., Kaverina, L. P., & Gorkin, V. Z. (1976) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1976.tb04462.x · Cited by 440
Moser, H. (1981) · doi:10.1212/wnl.31.10.1241 · Cited by 396
Self-citationSingh, I., Moser, A. E., Goldfischer, S., & Moser, H. W. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.13.4203 · Cited by 348
Self-citationMigeon, B. R., Moser, H. W., Moser, A. B., Axelman, J., Sillence, D., & Norum, R. A. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.8.5066 · Cited by 282 · cited 1×
“There was co-segregation of both adrenoleukodystrophy and the glucose-6-phosphate dehydrogenase variant in 18 informative offspring of doubly heterozygous mothers, suggesting a close proximity of these two genes on the X chromosome (Migeon et al., 1981).”
BackgroundSelf-citationMoser, A. E., Singh, I., Brown, F. R., Solish, G. I., Kelley, R. I., Benke, P. J., & Moser, H. W. (1984) · New England Journal of Medicine · doi:10.1056/nejm198405033101802 · Cited by 271
Self-citationAdrenoleukodystrophy: Survey of 303 cases: Biochemistry, diagnosis, and therapy
Moser, H. W., Moser, A. E., Singh, I., & O'Neill, P. (1984) · Annals of Neurology · doi:10.1002/ana.410160603 · Cited by 259
Self-citationSingh, I., Moser, A. E., Moser, H. W., & Kishimoto, Y. (1984) · Pediatric Research · doi:10.1203/00006450-198403000-00016 · Cited by 234
Self-citationKelley, R. I., Datta, N. S., Dobyns, W. B., Hajra, A. K., Moser, A. B., Noetzel, M. J., Zackai, E. H., Moser, H. W., Opitz, J. M., & Reynolds, J. F. (1986) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320230404 · Cited by 219
Self-citationAdrenoleukodystrophy: Elevated C26 fatty acid in cultured skin fibroblasts
Moser, H. W., Moser, A. B., Kawamura, N., Murphy, J., Suzuki, K., Schaumburg, H., & Kishimoto, Y. (1980) · Annals of Neurology · doi:10.1002/ana.410070607 · Cited by 210 · cited 2×
“The procedure for measurement of very long chain fatty acids in plasma has been described in detail (Moser et al., 1980).”
BackgroundMethodSelf-citationRizzo, W. B., Watkins, P. A., Phillips, M. W., Cranin, D., Campbell, B. D., & Avigan, J. (1986) · Neurology · doi:10.1212/wnl.36.3.357 · Cited by 153
Self-citation
Research works printed but not linked: 1
- Moser H. W. Naidu S. Kumar A. J.andRosenbaum A. E.The adrenoleukodystrophies.Crit. Rev. Neurobiol.(1986b) in press.
Cited by
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
Schönfeld, P., & Reiser, G. (2016) · Aging and disease · doi:10.14336/ad.2015.0823 · Cited by 67
“X-ALD is a severe neurodegenerative disorder resulting from defective ABCD1 transporter protein [64].”
BackgroundInfluentialThe Adrenal Cortex and its Disorders
Miller, W. L. (2009) · Brook's Clinical Pediatric Endocrinology · doi:10.1002/9781444316728.ch13 · Cited by 50
Adrenal cortex and its disorders
Miller, W. L., & Flück, C. E. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-4858-7.00022-6 · Cited by 60
Treatment of adrenoleukodystrophy with bone marrow transplantation
Malm, G., Ringdén, O., Anvret, M., von Döbeln, U., Hagenfeldt, L., Isberg, B., Knuutila, S., Nennesmo, I., Winiarski, J., & Marcus, C. (1997) · Acta Paediatrica · doi:10.1111/j.1651-2227.1997.tb08918.x · Cited by 38
Manor, J., Chung, H., Bhagwat, P. K., & Wangler, M. F. (2021) · Journal of Neuroscience Research · doi:10.1002/jnr.24953 · Cited by 32
“The biochemical fingerprint of X- ALD is the elevation of very longchain fatty acids (VLCFAs), which are saturated fatty acids comprised of 22- carbon backbone or more, and in particular, the significant elevation of hexacosanoic acid (C26:0) (Watkins et al., 1987).”
BackgroundThe Adrenal Cortex and Its Disorders
Miller, W. L., Achermann, J. C., & Flück, C. E. (2008) · Elsevier eBooks · doi:10.1016/b978-141604090-3.50017-x · Cited by 33
Regulation of the metabolism of polyunsaturated fatty acids
Hagve, T., Christensen, E., Grønn, M., & Christophersen, B. O. (1988) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365518809168292 · Cited by 23
Christensen, E., Grønn, M., Hagve, T., Kase, B. F., & Christophersen, B. O. (1989) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(89)90067-2 · Cited by 22
Molecular Biomarkers in Multiple Sclerosis and Its Related Disorders: A Critical Review
Gul, M., Jafari, A. A., Shah, M., Mirmoeeni, S., Haider, S. U., Moinuddin, S., & Chaudhry, A. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176020 · Cited by 17
“The levels of the biomarkers mentioned cannot be used as prognostic indicators [144,145].”
Backgroundvan der Knaap, M. S., & Valk, J. (1995) · Springer eBooks · doi:10.1007/978-3-662-03078-3_19 · Cited by 16
The Adrenal Cortex and Its Disorders
Miller, W. L., Flück, C. E., Breault, D. T., & Feldman, B. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-62520-3.00014-2 · Cited by 35
Adrenomyeloneuropathy—report on a family
HOLMBERG, B. H., Hägg, E., & Hagenfeldt, L. (1991) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1991.tb00485.x · Cited by 8
Jorge, P., Quelhas, D., & Nogueira, A. (1992) · Journal of Inherited Metabolic Disease · doi:10.1007/bf00711315 · Cited by 4
“In AMN patients the spinal cord and peripheral nerves are mainly involved and its course may extend over decades ( Watkins et al 1987; Moser 1989).”
BackgroundX-linked adrenoleukodystrophy presenting as Addison’s disease: Figure 1
Morell, B. K., Teichler, J., Budak, K., Vollenweider, J., & Pavlicek, V. (2010) · BMJ Case Reports · doi:10.1136/bcr.11.2009.2419 · Cited by 4
Valk, J., & van der Knaap, M. S. (1989) · Springer eBooks · doi:10.1007/978-3-662-02568-0_16 · Cited by 3
The Adrenal Cortex and its Disorders
Miller, W. L. (2005) · Wiley eBooks · doi:10.1002/9780470987117.ch15 · Cited by 4
Pietrzyk, J. J., Turowska-Heydel, D., Klimek, M., Kaczmarski, F., & Kałuza, J. (1990) · Clinical Pediatrics · doi:10.1177/000992289002900814 · Cited by 1
Anesthetic management of a case with adrenoleukodistrophy and mitochondrial myopathy
Uzun, Ş., & Şener, Z. (2014) · Journal of Clinical and Experimental Investigations · doi:10.5799/ahinjs.01.2014.03.0440
“Değişik santral sinir sistemi problemleri ve adrenal yetmezlik tablosu birlikte görülür [1].”
(2023) · Journal of Clinical & Experimental Immunology · doi:10.33140/jcei.08.03.04
Metadata
- Authors
- Watkins, P. A., Naidu, S., & Moser, H. W.
- Affiliations
- Johns Hopkins University (US)
- ORCID
- Watkins, P. A.
- Venue
- Journal of Inherited Metabolic Disease
- Publisher
- Wiley
- Published
- 1987-03
- Volume
- 10
- Issue
- S1
- Pages
- 46-53
- ISSN
- 0141-8955 (ISSN-L)
- 1573-2665
- OpenAlex
- W2075066897
- Cited by
- 20
- References
- 20
- Citations by year
- 2023: 1 · 2021: 2 · 2020: 1 · 2016: 1 · 2014: 2
- FWCI
- 1.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Inherited Metabolic Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Health Sciences › Medicine › Dermatology › Genetic and rare skin diseases.
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- adrenoleukodystrophy, very long chain fatty acids, hexacosanoic acid, X-linked recessive disorder, prenatal diagnosis, carrier detection, dietary restriction, triolein, oleic acid, clofibrate, L-carnitine, diagnosis, treatment
- MeSH terms
- Adrenoleukodystrophy, Diffuse Cerebral Sclerosis of Schilder, Child, Chromosome Mapping, Fatty Acids, Female, Genetic Carrier Screening, Humans, Phenotype, Pregnancy, Prenatal Diagnosis, X Chromosome, Bone Marrow Transplantation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.